CDK12 paradox in breast Cancer: Loss-of-Function fusion and oncogenic amplification as dual therapeutic Targets.
0/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
APA
Yu C, Yao F, et al. (2026). CDK12 paradox in breast Cancer: Loss-of-Function fusion and oncogenic amplification as dual therapeutic Targets.. Human pathology, 106047. https://doi.org/10.1016/j.humpath.2026.106047
MLA
Yu C, et al.. "CDK12 paradox in breast Cancer: Loss-of-Function fusion and oncogenic amplification as dual therapeutic Targets.." Human pathology, 2026, pp. 106047.
PMID
41577204 ↗
같은 제1저자의 인용 많은 논문 (5)
- Global Quantitative Dynamics and Early Warning Signals of Hepatocellular Carcinoma: Integrating Theoretical Modeling with Experimental Validation.
- Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases.
- [F]FDG PET/CT for outcome prediction in diffuse large B-cell lymphoma treated with polatuzumab vedotin-containing regimens.
- Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.
- Ossifying fibromyxoid tumor with a novel mutation (c.1624G>A) unresponsive to alpelisib: A case report.